EDMONTON, July 12 /CNW/ - CardioMetabolics Inc., a Canadian
biopharmaceutical company, announced today that all approvals have been
received authorizing the start of their Phase II "Mini-METRxICS" Clinical
Trial, which is aimed at reducing Intensive Care Unit (ICU) stays in geriatric
patients undergoing cardiopulmonary bypass surgery. Dr. Ruth Collins-Nakai,
CMI's Chief Medical Officer commented that, "we are excited to start this
trial of a drug that has the potential to help such a large number of patients
globally. According to the American Heart Association, in the US alone, each
year more than 750,000 patients undergo open heart surgical procedures!"
